FIELD: biotechnology.
SUBSTANCE: invention relates to a multispecific antigen-binding protein, as well as an antigen-binding protein. Compositions and host cells for expression of said proteins are also disclosed. Invention also relates to a pharmaceutical composition for treating a disorder in which antigen activity has a negative effect.
EFFECT: invention enables effective heterodimerisation of antigen-binding proteins.
25 cl, 12 dwg, 11 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODY-LIKE BINDING PROTEINS WITH DOUBLE VARIABLE REGIONS HAVING CROSS-CROSS ORIENTATION OF BINDING REGIONS | 2012 |
|
RU2823693C2 |
PSEUDO-FAB BASED MULTISPECIFIC BINDING PROTEINS | 2019 |
|
RU2820254C2 |
TRISPECIFIC BINDING PROTEINS BINDING CD38, CD28 AND CD3, AS WELL AS METHODS OF USE FOR TREATING VIRAL INFECTION | 2019 |
|
RU2820351C2 |
LY6G6D ANTIBODIES AND METHODS OF USE | 2020 |
|
RU2818569C1 |
TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING CROSSOVER FORMAT WITH DOUBLE VARIABLE DOMAIN (CODV) FOR TREATING INFECTION CAUSED BY HIV | 2020 |
|
RU2820164C2 |
TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
Authors
Dates
2024-10-01—Published
2019-12-23—Filed